Our results suggest that these peptides are capable of inducing specific cytotoxic cytokines secretion against FJX1-expressing cancer cells and serve as a potential vaccine-based therapy for NPC patients. This evidence concerns the gene FJX1 and nasopharyngeal carcinoma.